Dr. Bonaca is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13199 E Montview Blvd
Suite 200
Aurora, CO 80045
Summary
- Dr. Marc Bonaca is a cardiologist in Aurora, CO and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital and University of Colorado Hospital. He received his medical degree from University of Connecticut School of Medicine and has been in practice 14 years. He specializes in adult cardiology and vascular medicine and is experienced in peripheral vascular disease.
Education & Training
- Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Vascular Medicine, 2010 - 2011
- Harvard School of Public HealthMPH, Public Health, 2008 - 2011
- Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2006 - 2009
- Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2006
- Uconn School Of MedicineClass of 2003
Certifications & Licensure
- CO State Medical License 2019 - 2025
- MA State Medical License 2005 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) Start of enrollment: 2007 Sep 01
- Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Start of enrollment: 2010 Oct 01
- Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events Start of enrollment: 2013 Apr 25
- Join now to see all
Publications & Presentations
PubMed
- 268 citationsRivaroxaban in Peripheral Artery Disease after Revascularization.Marc P Bonaca, Rupert M Bauersachs, Sonia S Anand, E Sebastian Debus, Mark R Nehler
The New England Journal of Medicine. 2020-05-21 - 1460 citationsDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato
The New England Journal of Medicine. 2019-01-24 - 1662 citationsSGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular ...Thomas A Zelniker, Stephen D. Wiviott, Itamar Raz, KyungAh Im, Erica L. Goodrich
Lancet. 2019-01-05
Journal Articles
- Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesNicholas A Marston, Marc P Bonaca, Petr Jarolim, Deepak L Bhatt, Stephen D Wiviott, Eugene Braunwald, Marc S Sabatine, JAMA Cardiology
- ASCVD Risk and Statin Use in PADMarc Bonaca, MD, JACC: Cardiovascular Imaging
- Rivaroxaban in Peripheral Artery Disease After RevascularizationMarc Bonaca, MD, The New England Journal of Medicine
- Join now to see all
Lectures
- Novel Approaches in Diabetic Patients After PCI: Role of SGLT2 Inhibitors and Potent Antiplatelet Therapy (THEMIS)CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
- The Role of Antiplatelet Agents in Patients With Diabetes and Coronary DiseaseCRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
- Highlights in Peripheral Artery Disease2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Join now to see all
Authored Content
- What Is Optimal Medical Therapy for CLTI? Can We Move the Needle with Drugs Alone?October 2020
- Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesAugust 2020
- ASCVD Risk and Statin Use in PADJuly 2020
- Rivaroxaban in Peripheral Artery Disease After RevascularizationMarch 2020
- Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients with Multivessel Coronary DiseaseJanuary 2018
- Reply Cost-Effectiveness of Long-Term Ticagrelor in Patients with Prior Myocardial Infarction: Analysis by SubgroupsJanuary 2018
- Join now to see all
Press Mentions
- Updated Guidelines Tackle Management of Peripheral Arterial and Aortic DiseasesOctober 8th, 2024
- Interactive Map Highlights PAD Amputation Risks; Experts Call for ActionSeptember 3rd, 2024
- ABYSS: Safety Signal Seen When Beta-Blockers Stopped in Post-MI PatientsAugust 30th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: